NASDAQ:AMGN - Nasdaq - US0311621009 - Common Stock - Currency: USD
Overall AMGN gets a fundamental rating of 5 out of 10. We evaluated AMGN against 557 industry peers in the Biotechnology industry. AMGN scores excellent on profitability, but there are some minor concerns on its financial health. AMGN has a correct valuation and a medium growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 6.64% | ||
ROE | 95.59% | ||
ROIC | 11.3% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 25.22% | ||
PM (TTM) | 17.39% | ||
GM | 64.07% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 8.7 | ||
Debt/FCF | 5.26 | ||
Altman-Z | 1.47 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.17 | ||
Quick Ratio | 0.88 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 14.24 | ||
Fwd PE | 13.49 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 14.56 | ||
EV/EBITDA | 14.62 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.2% |
295.56
+0.34 (+0.12%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | 3.2% |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 14.24 | ||
Fwd PE | 13.49 | ||
P/S | 4.66 | ||
P/FCF | 14.56 | ||
P/OCF | 13.04 | ||
P/B | 25.6 | ||
P/tB | N/A | ||
EV/EBITDA | 14.62 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 6.64% | ||
ROE | 95.59% | ||
ROCE | 12.97% | ||
ROIC | 11.3% | ||
ROICexc | 13.03% | ||
ROICexgc | 56.9% | ||
OM | 25.22% | ||
PM (TTM) | 17.39% | ||
GM | 64.07% | ||
FCFM | 31.98% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 8.7 | ||
Debt/FCF | 5.26 | ||
Debt/EBITDA | 3.81 | ||
Cap/Depr | 22.89% | ||
Cap/Sales | 3.74% | ||
Interest Coverage | 250 | ||
Cash Conversion | 85.93% | ||
Profit Quality | 183.97% | ||
Current Ratio | 1.17 | ||
Quick Ratio | 0.88 | ||
Altman-Z | 1.47 |